[Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL
Wiener medizinische Wochenschrift Pub Date : 2023-10-01 Epub Date: 2022-12-21 DOI:10.1007/s10354-022-00989-0
Daniel Cejka, Robert Wakolbinger-Habel, Emanuel Zitt, Astrid Fahrleitner-Pammer, Karin Amrein, Hans Peter Dimai, Christian Muschitz
{"title":"[Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].","authors":"Daniel Cejka,&nbsp;Robert Wakolbinger-Habel,&nbsp;Emanuel Zitt,&nbsp;Astrid Fahrleitner-Pammer,&nbsp;Karin Amrein,&nbsp;Hans Peter Dimai,&nbsp;Christian Muschitz","doi":"10.1007/s10354-022-00989-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Definition and epidemiology: </strong>Chronic kidney disease (CKD): abnormalities of kidney structure or function, present for over 3 months. Staging of CKD is based on GFR and albuminuria (not graded). Osteoporosis: compromised bone strength (low bone mass, disturbance of microarchitecture) predisposing to fracture. By definition, osteoporosis is diagnosed if the bone mineral density T‑score is ≤ -2.5. Furthermore, osteoporosis is diagnosed if a low-trauma (inadequate trauma) fracture occurs, irrespective of the measured T‑score (not graded). The prevalence of osteoporosis, osteoporotic fractures and CKD is increasing worldwide (not graded). PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER (CKD-MBD): Definition of CKD-MBD: a systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following: abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism; renal osteodystrophy; vascular calcification (not graded). Increased, normal or decreased bone turnover can be found in renal osteodystrophy (not graded). Depending on CKD stage, routine monitoring of calcium, phosphorus, alkaline phosphatase, PTH and 25-OH-vitamin D is recommended (2C). Recommendations for treatment of CKD-MBD: Avoid hypercalcemia (1C). In cases of hyperphosphatemia, lower phosphorus towards normal range (2C). Keep PTH within or slightly above normal range (2D). Vitamin D deficiency should be avoided and treated when diagnosed (1C).</p><p><strong>Diagnosis and risk stratification of osteoporosis in ckd: </strong>Densitometry (using dual X‑ray absorptiometry, DXA): low T‑score correlates with increased fracture risk across all stages of CKD (not graded). A decrease of the T‑score by 1 unit approximately doubles the risk for osteoporotic fracture (not graded). A T-score ≥ -2.5 does not exclude osteoporosis (not graded). Bone mineral density of the lumbar spine measured by DXA can be increased and therefore should not be used for the diagnosis or monitoring of osteoporosis in the presence of aortic calcification, osteophytes or vertebral fracture (not graded). FRAX can be used to aid fracture risk estimation in all stages of CKD (1C). Bone turnover markers can be measured in individual cases to monitor treatment (2D). Bone biopsy may be considered in individual cases, especially in patients with CKD G5 (eGFR < 15 ml/min/1.73 m<sup>2</sup>) or CKD 5D (dialysis).</p><p><strong>Specific treatment of osteoporosis in patients with ckd: </strong>Hypocalcemia should be treated and serum calcium normalized before initiating osteoporosis therapy (1C). CKD G1-G2 (eGFR ≥ 60 ml/min/1.73 m<sup>2</sup>): treat osteoporosis as recommended for the general population (1A). CKD G3-G5D (eGFR < 60 ml/min/1.73 m<sup>2</sup> to dialysis): treat CKD-MBD first before initiating osteoporosis treatment (2C). CKD G3 (eGFR 30-59 ml/min/1.73 m<sup>2</sup>) with PTH within normal limits and osteoporotic fracture and/or high fracture risk according to FRAX: treat osteoporosis as recommended for the general population (2B). CKD G4-5 (eGFR < 30 ml/min/1.73 m<sup>2</sup>) with osteoporotic fracture (secondary prevention): Individualized treatment of osteoporosis is recommended (2C). CKD G4-5 (eGFR < 30 ml/min/1.73 m<sup>2</sup>) and high fracture risk (e.g. FRAX score > 20% for a major osteoporotic fracture or > 5% for hip fracture) but without prevalent osteoporotic fracture (primary prevention): treatment of osteoporosis may be considered and initiated individually (2D). CKD G4-5D (eGFR < 30 ml/min/1.73 m<sup>2</sup> to dialysis): Calcium should be measured 1-2 weeks after initiation of antiresorptive therapy (1C).</p><p><strong>Physical medicine and rehabilitation: </strong>Resistance training prioritizing major muscle groups thrice weekly (1B). Aerobic exercise training for 40 min four times per week (1B). Coordination and balance exercises thrice weekly (1B). Flexibility exercise 3-7 times per week (1B).</p>","PeriodicalId":23882,"journal":{"name":"Wiener medizinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516794/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiener medizinische Wochenschrift","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s10354-022-00989-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Definition and epidemiology: Chronic kidney disease (CKD): abnormalities of kidney structure or function, present for over 3 months. Staging of CKD is based on GFR and albuminuria (not graded). Osteoporosis: compromised bone strength (low bone mass, disturbance of microarchitecture) predisposing to fracture. By definition, osteoporosis is diagnosed if the bone mineral density T‑score is ≤ -2.5. Furthermore, osteoporosis is diagnosed if a low-trauma (inadequate trauma) fracture occurs, irrespective of the measured T‑score (not graded). The prevalence of osteoporosis, osteoporotic fractures and CKD is increasing worldwide (not graded). PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER (CKD-MBD): Definition of CKD-MBD: a systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following: abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism; renal osteodystrophy; vascular calcification (not graded). Increased, normal or decreased bone turnover can be found in renal osteodystrophy (not graded). Depending on CKD stage, routine monitoring of calcium, phosphorus, alkaline phosphatase, PTH and 25-OH-vitamin D is recommended (2C). Recommendations for treatment of CKD-MBD: Avoid hypercalcemia (1C). In cases of hyperphosphatemia, lower phosphorus towards normal range (2C). Keep PTH within or slightly above normal range (2D). Vitamin D deficiency should be avoided and treated when diagnosed (1C).

Diagnosis and risk stratification of osteoporosis in ckd: Densitometry (using dual X‑ray absorptiometry, DXA): low T‑score correlates with increased fracture risk across all stages of CKD (not graded). A decrease of the T‑score by 1 unit approximately doubles the risk for osteoporotic fracture (not graded). A T-score ≥ -2.5 does not exclude osteoporosis (not graded). Bone mineral density of the lumbar spine measured by DXA can be increased and therefore should not be used for the diagnosis or monitoring of osteoporosis in the presence of aortic calcification, osteophytes or vertebral fracture (not graded). FRAX can be used to aid fracture risk estimation in all stages of CKD (1C). Bone turnover markers can be measured in individual cases to monitor treatment (2D). Bone biopsy may be considered in individual cases, especially in patients with CKD G5 (eGFR < 15 ml/min/1.73 m2) or CKD 5D (dialysis).

Specific treatment of osteoporosis in patients with ckd: Hypocalcemia should be treated and serum calcium normalized before initiating osteoporosis therapy (1C). CKD G1-G2 (eGFR ≥ 60 ml/min/1.73 m2): treat osteoporosis as recommended for the general population (1A). CKD G3-G5D (eGFR < 60 ml/min/1.73 m2 to dialysis): treat CKD-MBD first before initiating osteoporosis treatment (2C). CKD G3 (eGFR 30-59 ml/min/1.73 m2) with PTH within normal limits and osteoporotic fracture and/or high fracture risk according to FRAX: treat osteoporosis as recommended for the general population (2B). CKD G4-5 (eGFR < 30 ml/min/1.73 m2) with osteoporotic fracture (secondary prevention): Individualized treatment of osteoporosis is recommended (2C). CKD G4-5 (eGFR < 30 ml/min/1.73 m2) and high fracture risk (e.g. FRAX score > 20% for a major osteoporotic fracture or > 5% for hip fracture) but without prevalent osteoporotic fracture (primary prevention): treatment of osteoporosis may be considered and initiated individually (2D). CKD G4-5D (eGFR < 30 ml/min/1.73 m2 to dialysis): Calcium should be measured 1-2 weeks after initiation of antiresorptive therapy (1C).

Physical medicine and rehabilitation: Resistance training prioritizing major muscle groups thrice weekly (1B). Aerobic exercise training for 40 min four times per week (1B). Coordination and balance exercises thrice weekly (1B). Flexibility exercise 3-7 times per week (1B).

Abstract Image

Abstract Image

[慢性肾脏病患者骨质疏松症的诊断和治疗:奥地利骨与矿物研究学会(ÖGKM)、奥地利物理与康复医学学会(ÖGPMR)和奥地利肾病学会(ÖGN)的联合指南]。
定义和流行病学:慢性肾脏疾病(CKD):肾脏结构或功能异常,存在时间超过3个月。CKD的分期是基于肾小球滤过率和蛋白尿(未分级)。骨质疏松症:骨强度受损(骨量低,微结构紊乱)易骨折。根据定义,如果骨密度T评分为 ≤ -2.5.此外,如果发生低创伤(创伤不足)骨折,无论测量的T评分如何(未分级),都会诊断为骨质疏松症。骨质疏松症、骨质疏松性骨折和CKD的患病率在全球范围内呈上升趋势(未分级)。慢性肾脏病-矿物质和骨骼疾病(CKD-MBD)的病理、诊断和治疗:CKD-MBD的定义:CKD引起的一种全身性矿物质和骨骼代谢紊乱,表现为以下一种或多种:钙、磷、甲状旁腺激素或维生素D代谢异常;肾性骨营养不良;血管钙化(未分级)。肾性骨营养不良(未分级)可发现骨转换增加、正常或减少。根据CKD分期,建议对钙、磷、碱性磷酸酶、甲状旁腺激素和25-OH维生素D进行常规监测(2C)。CKD-MBD的治疗建议:避免高钙血症(1C)。在高磷血症的情况下,将磷降低到正常范围(2C)。将PTH保持在或略高于正常范围(2D)。诊断时应避免并治疗维生素D缺乏症(1C)。ckd骨质疏松症的诊断和风险分层:密度测定法(使用双X射线吸收仪,DXA):低T评分与ckd所有阶段骨折风险增加相关(未分级)。T评分降低1个单位,骨质疏松性骨折(未分级)的风险约增加一倍。T型芯 ≥ -2.5并不排除骨质疏松症(未分级)。DXA测量的腰椎骨密度可能会增加,因此不应用于诊断或监测主动脉钙化、骨赘或脊椎骨折(未分级)时的骨质疏松症。FRAX可用于帮助评估CKD所有阶段的骨折风险(1C)。骨转换标志物可以在个别病例中进行测量,以监测治疗(2D)。个别病例可考虑进行骨活检,尤其是CKD G5(eGFR 2) CKD 5D(透析)。CKD患者骨质疏松症的特殊治疗:在开始骨质疏松症治疗之前,应治疗低钙血症并使血清钙正常化(1C)。CKD G1-G2(eGFR ≥ 60 ml/min/1.73 m2):按照一般人群的建议治疗骨质疏松症(1A)。CKD G3-G5D(eGFR 2至透析):在开始骨质疏松症治疗之前首先治疗CKD-MBD(2C)。CKD G3(eGFR 30-59 ml/min/1.73 m2)PTH在正常范围内,根据FRAX,骨质疏松性骨折和/或高骨折风险:按照普通人群的建议治疗骨质疏松症(2B)。CKD G4-5(eGFR 2) 骨质疏松性骨折(二级预防):建议对骨质疏松症进行个性化治疗(2C)。CKD G4-5(eGFR 2) 骨折风险高(例如FRAX评分 > 20%用于严重骨质疏松性骨折或 > 5%用于髋部骨折),但没有普遍的骨质疏松性骨折(一级预防):骨质疏松症的治疗可以单独考虑和开始(2D)。CKD G4-5D(eGFR 2至透析):应在开始抗再吸收治疗后1-2周测量钙(1C)。物理医学和康复:每周三次阻力训练,优先考虑主要肌肉群(1B)。40人有氧运动训练 每周至少四次(1B)。每周进行三次协调和平衡练习(1B)。柔韧性训练每周3-7次(1B)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Wiener medizinische Wochenschrift
Wiener medizinische Wochenschrift MEDICINE, GENERAL & INTERNAL-
CiteScore
2.50
自引率
0.00%
发文量
79
期刊介绍: ''From the microscope to clinical application!'', Scientists from all European countries make available their recent research results and practical experience through Wiener Medizinische Wochenschrift, the renowned English- and German-language forum. Both original articles and reviews on a broad spectrum of clinical and preclinical medicine are presented within the successful framework of thematic issues compiled by guest editors. Selected cutting-edge topics, such as dementia, geriatric oncology, Helicobacter pylori and phytomedicine make the journal a mandatory source of information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信